Get Adobe Flash player
Supportive Oncology Advancing the Care of Cancer Patients with Vertebral Compression Fractures—A Radiation Oncology Expert Panel Discussion Moderator: Jon Strasser, MD Radiation Oncologist, Thomas Jefferson University and Helen F Graham Cancer Center Expert Panel Members: Neha Amin, MD, 1 Gregg Dickerson, MD, 2 Nancy Cersonsky, MD, 3 Michelle Stinauer, MD, 1 Brian Petersen, MD 4 and Timothy Birney, MD 5 1. Radiation Oncologist, University of Colorado Denver; 2. Radiation Oncologist, Denver CyberKnife; 3. Radiation Oncologist, Valley Radiotherapy Associates Medical Group, Swedish Medical Center, Englewood; 4. Interventional Radiologist, University of Colorado Hospital; 5. Orthopedic Surgeon, Western Orthopaedics, Denver Introduction A closed roundtable discussion on ‘Advancing the Care of Cancer Patients with Vertebral Compression Fractures’ was held in Denver, Colorado, on November 16, 2010. The attendees included six invited local experts—four radiation oncologists, an interventional radiologist, and an orthopedic surgeon. The moderator, Jon Strasser, MD, a radiation oncologist, opened the meeting by explaining that its goal was to identify the barriers to managing vertebral compression fractures (VCFs) in cancer patients and discuss available treatment options. The focus would be on three topics: current treatment practice for spinal metastases; treatment goals in the presence of VCFs; and minimally invasive procedures for VCFs. Each topic is allocated a separate section of the following report of the discussion. Keywords Radiation oncology vertebral compression fracture, cancer patients, spinal metastases, cancer treatment options Disclosure: Jon Strasser, MD, is a consultant for Medtronic. The Kyphon Products Division of Medtronic hosted and supported the expert panel discussion. Received: October 5, 2011 Accepted: January 9, 2012 Citation: Oncology & Hematology Review, 2012;8(1):12–7 Correspondence: Jon Strasser, MD, Thomas Jefferson University and Helen F Graham Cancer Center, Radiation Oncology, 4701 Ogletown-Stanton Rd., S-1110, Newark, DE 19713. E: Support: The publication of this article was funded by Medtronic. The views and opinions expressed are those of the panel members and not necessarily those of Medtronic. Section 1. Current Treatment Practice for Spinal Metastases Dr Strasser, a radiation oncologist, initiated the presentation with an overview of the manifestation of spinal metastases, stating that these develop in about half of all cancer patients. The median survival after bone metastases is 12 months with prostate cancer and five months with lung cancer, but it is two to three years in patients with breast cancer and multiple myeloma. 1–4 Therefore, it is important to address bone metastases in these patients. Treatment is especially important if patients develop fractures and experience pain. Bone metastases lead to skeletal-related events, including fractures, pain, spinal cord compression, and hypercalcemia. Spinal metastases can be classified as osteolytic or osteoblastic; radiosensitive or radioresistant; or by spinal cord location. Osteoblastic vertebral lesions, which are common in patients with prostate cancer, are characterized by increased bone density and decreased bone stiffness. Osteolytic bone lesions, which are common in patients with 12 multiple myeloma, are characterized by decreased bone density, bone stiffness, and bone strength. Patients with osteolytic lesions have a higher risk of fractures. When managing patients with spinal metastases, it is important to consider neurological aspects (e.g., degree of epidural cord compression, myelopathy, or radiculopathy), oncological aspects (e.g., tumor histology, radiosensitivity, and prognosis), mechanical instability, systemic disease, and patient preference for treatment. Treatment goals are generally achieved by using a combination of complementary systemic and local therapies. Systemic therapy is used to improve patient survival, slow the progression of the disease, and prevent future events. Systemic therapy options for spinal metastases include steroids, bisphosphonates, chemotherapy, hormonal agents, and radiopharmaceuticals. Local therapies include surgery (e.g., spine stabilization) and radiation. Local therapy is used to control pain, restore anatomy, ablate a systemic tumor, and stabilize a fracture. © TOUCH BRIEFINGS 2012